News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
333,875 Results
Type
Article (20078)
Company Profile (128)
Press Release (313669)
Multimedia
Podcasts (71)
Webinars (11)
Section
Business (105483)
Career Advice (879)
Deals (18558)
Drug Delivery (97)
Drug Development (50827)
Employer Resources (79)
FDA (7707)
Job Trends (7749)
News (186070)
Policy (17358)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (736)
Accelerated approval (3)
Adcomms (17)
Allergies (40)
Alliances (27868)
ALS (54)
Alzheimer's disease (640)
Antibody-drug conjugate (ADC) (89)
Approvals (7718)
Artificial intelligence (141)
Autoimmune disease (15)
Automation (5)
Bankruptcy (177)
Best Places to Work (5554)
BIOSECURE Act (13)
Biosimilars (97)
Biotechnology (57)
Bladder cancer (31)
Brain cancer (19)
Breast cancer (109)
Cancer (1047)
Cardiovascular disease (113)
Career advice (712)
Career pathing (20)
CAR-T (55)
Cell therapy (151)
Cervical cancer (5)
Clinical research (42712)
Collaboration (462)
Compensation (170)
Complete response letters (23)
COVID-19 (1099)
CRISPR (22)
C-suite (146)
Cystic fibrosis (58)
Data (1116)
Decentralized trials (2)
Denatured (18)
Depression (24)
Diabetes (139)
Diagnostics (1815)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (81)
Drug pricing (109)
Drug shortages (30)
Duchenne muscular dystrophy (60)
Earnings (39070)
Editorial (32)
Employer branding (10)
Employer resources (73)
Events (48652)
Executive appointments (447)
FDA (8292)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (313)
Gene editing (47)
Generative AI (18)
Gene therapy (144)
GLP-1 (594)
Government (1854)
Grass and pollen (2)
Guidances (19)
Healthcare (5913)
Huntington's disease (13)
IgA nephropathy (20)
Immunology and inflammation (85)
Indications (17)
Infectious disease (1181)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (56)
Interviews (116)
IPO (7386)
IRA (45)
Job creations (2432)
Job search strategy (648)
Kidney cancer (7)
Labor market (22)
Layoffs (278)
Leadership (14)
Legal (4119)
Liver cancer (31)
Lung cancer (158)
Lymphoma (85)
Machine learning (2)
Management (30)
Manufacturing (201)
MASH (49)
Medical device (1969)
Medtech (1972)
Mergers & acquisitions (11430)
Metabolic disorders (494)
Multiple sclerosis (48)
NASH (20)
Neurodegenerative disease (49)
Neuropsychiatric disorders (20)
Neuroscience (951)
NextGen: Class of 2025 (2362)
Non-profit (907)
Northern California (1071)
Now hiring (21)
Obesity (311)
Opinion (190)
Ovarian cancer (33)
Pain (66)
Pancreatic cancer (36)
Parkinson's disease (86)
Partnered (11)
Patents (142)
Patient recruitment (45)
Peanut (16)
People (33487)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13368)
Phase II (18067)
Phase III (14520)
Pipeline (714)
Policy (121)
Postmarket research (1618)
Preclinical (4662)
Press Release (29)
Prostate cancer (61)
Psychedelics (16)
Radiopharmaceuticals (161)
Rare diseases (244)
Real estate (3175)
Recruiting (29)
Regulatory (12538)
Reports (22)
Research institute (819)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (59)
Series A (57)
Series B (33)
Service/supplier (7)
Sickle cell disease (36)
Southern California (1025)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2010)
State (2)
Stomach cancer (9)
Supply chain (54)
Tariffs (29)
The Weekly (51)
United States (10089)
Vaccines (270)
Venture capitalists (28)
Weight loss (241)
Women's health (14)
Worklife (7)
Date
Last 7 days (233)
Last 30 days (1132)
Last 365 days (16702)
2025 (4820)
2024 (17680)
2023 (19643)
2022 (25880)
2021 (26666)
2020 (24918)
2019 (20088)
2018 (15621)
2017 (17258)
2016 (16213)
2015 (18840)
2014 (14817)
2013 (12562)
2012 (13489)
2011 (13820)
2010 (12744)
Location
Africa (409)
Alabama (23)
Alaska (1)
Arizona (65)
Arkansas (8)
Asia (24896)
Australia (3226)
California (2510)
Canada (1100)
China (321)
Colorado (96)
Connecticut (99)
Delaware (69)
Europe (51423)
Florida (438)
Georgia (55)
Idaho (16)
Illinois (249)
India (20)
Indiana (173)
Iowa (3)
Japan (118)
Kansas (62)
Kentucky (17)
Louisiana (2)
Maine (4)
Maryland (365)
Massachusetts (2121)
Michigan (48)
Minnesota (137)
Mississippi (1)
Missouri (27)
Montana (10)
Nebraska (11)
Nevada (17)
New Hampshire (8)
New Jersey (1028)
New Mexico (21)
New York (738)
North Carolina (496)
North Dakota (2)
Northern California (1071)
Ohio (81)
Oklahoma (5)
Oregon (21)
Pennsylvania (601)
Puerto Rico (11)
Rhode Island (17)
South America (608)
South Carolina (3)
Southern California (1025)
Tennessee (38)
Texas (332)
Utah (56)
Virginia (82)
Washington D.C. (43)
Washington State (216)
Wisconsin (20)
333,875 Results for "urogen pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
UroGen Pharma to Present at Upcoming Investor Conferences
January 30, 2025
·
1 min read
Press Releases
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
February 24, 2025
·
1 min read
Press Releases
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 7, 2025
March 10, 2025
·
2 min read
Press Releases
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
February 27, 2025
·
1 min read
Business
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
UroGen Pharma Ltd. today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team.
June 3, 2024
·
11 min read
Deals
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 7, 2024
UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) and an option (“Option”) to 15 new employees in connection with their employment with UroGen.
June 7, 2024
·
2 min read
Pharm Country
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
UroGen Pharma Ltd. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants.
June 17, 2024
·
4 min read
Pharm Country
UroGen Pharma to Participate at Upcoming May 2024 Investor Conferences
UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced that it will present at the following investor conferences in May.
May 7, 2024
·
1 min read
Pharm Country
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
UroGen Pharma Ltd. today shared additional details about the upcoming ENVISION virtual data event on Thursday, June 13, 2024, at 11:00 a.m. Eastern Time.
June 6, 2024
·
4 min read
Press Releases
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
March 10, 2025
·
19 min read
1 of 33,388
Next
